Alvotech is trading 3.05% down at ISK 636.00, with broader market pressure the clearest context for the decline. - September U.S. CPI was 3.7%, above the 3.6% forecast; Reuters said hotter inflation strengthened rate-hike bets and weighed on stocks. - On October 14, Alvotech announced an AVT29 European application for a proposed Eylea 8 mg biosimilar. The positive company news does not explain the October 15 move. - No specific Alvotech announcement explaining the October 15 move was found.